ReviewPathogens and global health2021
Zika virus pathogenesis and current therapeutic advances.
Review in Pathogens and global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- Beyond single-structure docking in anti-Zika discovery: toward translational molecular modeling.Journal of molecular modeling · 2026Article
- ZIKV NS3 disrupts Nrf2-mediated antioxidant defense and drives vascular smooth muscle cell damage and vascular dysfunction.Zoological research · 2026Article
- Dual role of Japanese encephalitis virus fusion loop peptide antibodies in Zika virus infection.PLoS neglected tropical diseases · 2026Article
- Zika virus: unraveling the complex interplay between viral pathogenesis and host immune defenses.Virology journal · 2026Review
- Progress in research on mosquito-borne viruses: Understanding infection, transmission, and control.Infectious diseases & immunity · 2026Review
- Neutrophils at the Maternal-Fetal Interface: Agents of Protection or Destruction?American journal of reproductive immunology (New York, N.Y. : 1989) · 2025Review
- A novel ZIKV-targeted scRNA-seq method for precise quantification of ZIKV RNA.Journal of virology · 2025Article
- Neural and endothelial cell-derived extracellular vesicles mediate Zika virus genome dissemination and productive infection in vivo.PloS one · 2025Article
- The Role of Epigallocatechin Gallate (EGCG) in Treatment and Management of Sexually Transmitted Viral Infections.Infectious disorders drug targets · 2025Review
- Zika virus tropism and pathogenesis: understanding clinical impacts and transmission dynamics.Virology journal · 2024Review
- Development of an Eco-Friendly Nanogel IncorporatingPharmaceutics · 2024Article
- Evaluation of the antiviral activity of new dermaseptin analogs against Zika virus.Biochemistry and biophysics reports · 2024Article
- Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy.Vaccine: X · 2024Review
- Review
- Investigation of the activity of baicalein towards Zika virus.BMC complementary medicine and therapies · 2023Article
- Zika Virus: A Systematic Review of Teratogenesis, Congenital Anomalies, and Child Mortality.Cureus · 2023Review
- Synthesis of copaiba (Copaifera officinalis) oil nanoemulsion and the potential against Zika virus: An in vitro study.PloS one · 2023Article
- Detection of Tropical Diseases Caused by Mosquitoes Using CRISPR-Based Biosensors.Tropical medicine and infectious disease · 2022Review
- The Role of Matrix Metalloproteinase in Inflammation with a Focus on Infectious Diseases.International journal of molecular sciences · 2022Review
- MiR-103a-3p Promotes Zika Virus Replication by Targeting OTU Deubiquitinase 4 to Activate p38 Mitogen-Activated Protein Kinase Signaling Pathway.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zika virus (ZIKV) is an emerging arthropod-borne flavivirus that, upon infection, results in teratogenic effects and neurological disorders. ZIKV infections pose serious global public health concerns, prompting scientists to increase research on antivirals and vaccines against the virus. These efforts are still ongoing as the pathogenesis and immune evasion mechanisms of ZIKV have not yet been fully elaborated. Currently, no specific vaccines or drugs have been approved for ZIKV; however, some are undergoing clinical trials. Notably, several strategies have been used to develop antivirals, including drugs that target viral and host proteins. Additionally, drug repurposing is preferred since it is less costly and takes less time than other strategies because the drugs used have already been approved for human use. Likewise, different platforms have been evaluated for the design of vaccines, including DNA, mRNA, peptide, protein, viral vectors, virus-like particles (VLPSs), inactivated-virus, and live-attenuated virus vaccines. These vaccines have been shown to induce specific humoral and cellular immune responses and reduce viremia and viral RNA both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.